{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:00:34Z","timestamp":1768370434323,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019778","name":"U.S. President's Malaria Initiative","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05709-8","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:55:09Z","timestamp":1765176909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study"],"prefix":"10.1186","volume":"25","author":[{"given":"Tigest","family":"Shifraw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Semira","family":"Abdelmenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayele","family":"Zewde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alemayehu","family":"Worku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adugna","family":"Abera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kebede","family":"Etana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheleme","family":"Chibsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Girma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiwot","family":"Teka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mumba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellora","family":"Karmarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yemane","family":"Berhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"5709_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1475-2875-11-84","volume":"11","author":"A Woyessa","year":"2012","unstructured":"Woyessa A, Deressa W, Ali A, Lindtj\u00f8rn B. Prevalence of malaria infection in Butajira area, south-central Ethiopia. Malar J. 2012;11:84.","journal-title":"Malar J"},{"key":"5709_CR2","volume":"2019","author":"T Deress","year":"2019","unstructured":"Deress T, Girma M. Plasmodium falciparum and Plasmodium vivax prevalence in Ethiopia: a systematic review and meta-analysis. Malar Res Treat. 2019;2019:7065064.","journal-title":"Malar Res Treat"},{"key":"5709_CR3","doi-asserted-by":"publisher","first-page":"e00011","DOI":"10.1128\/CMR.00011-19","volume":"32","author":"JK Baird","year":"2019","unstructured":"Baird JK. 8-aminoquinoline therapy for latent malaria. Clin Microbiol Rev. 2019;32:e00011-19.","journal-title":"Clin Microbiol Rev"},{"key":"5709_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001575","volume":"10","author":"NM Douglas","year":"2013","unstructured":"Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, Sugiarto P, et al. Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med. 2013;10:e1001575.","journal-title":"PLoS Med"},{"key":"5709_CR5","unstructured":"WHO. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria. Policy brief. Geneva, World Health Organization, 2016;32."},{"key":"5709_CR6","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015."},{"key":"5709_CR7","unstructured":"WHO. Guidelines for malaria, 13 August 2025. Geneva: World Health Organization; 2025."},{"key":"5709_CR8","unstructured":"P. vivax information hub. Plasmodium vivax malaria in Ethiopia. [cited 2025 Oct 20]. https:\/\/www.vivaxmalaria.org\/regions-countries\/africa\/p-vivax-malaria-ethiopia#1. Accessed 20 Oct 2025"},{"key":"5709_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.actatropica.2009.10.001","volume":"113","author":"AK Yeshiwondim","year":"2010","unstructured":"Yeshiwondim AK, Tekle AH, Dengela DO, Yohannes AM, Teklehaimanot A. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. Acta Trop. 2010;113:105\u201313.","journal-title":"Acta Trop"},{"key":"5709_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002299","volume":"14","author":"T Abreha","year":"2017","unstructured":"Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14:e1002299.","journal-title":"PLoS Med"},{"key":"5709_CR11","first-page":"601","volume":"67","author":"WHO Working Group","year":"1989","unstructured":"WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67:601\u201311.","journal-title":"Bull World Health Organ"},{"key":"5709_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/1475-2875-13-438","volume":"13","author":"A Tsegaye","year":"2014","unstructured":"Tsegaye A, Golassa L, Mamo H, Erko B. Glucose-6-phosphate dehydrogenase deficiency among malaria suspects attending Gambella hospital, southwest Ethiopia. Malar J. 2014;13:438.","journal-title":"Malar J"},{"key":"5709_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12936-018-2538-4","volume":"17","author":"A Assefa","year":"2018","unstructured":"Assefa A, Ali A, Deressa W, Tsegaye W, Abebe G, Sime H, et al. Glucose-6-phosphate dehydrogenase (G6PD) deficiency in Ethiopia: absence of common African and Mediterranean allelic variants in a nationwide study. Malar J. 2018;17:388.","journal-title":"Malar J"},{"key":"5709_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archinte.1962.03620140081013","volume":"109","author":"AR Tarlov","year":"1962","unstructured":"Tarlov AR, Brewer GJ, Carson PE, Alving AS. Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med. 1962;109:209\u201334.","journal-title":"Arch Intern Med"},{"key":"5709_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006230","volume":"12","author":"J Recht","year":"2018","unstructured":"Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12:e0006230.","journal-title":"PLoS Negl Trop Dis"},{"key":"5709_CR16","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. Malaria Diagnosis and Treatment Guideline. [Internet]. 2018. https:\/\/www.medbox.org\/preview\/5333fe20-1850-4d30-9fbe-731f1fcc7b89\/doc.pdf."},{"key":"5709_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552\u20139.","journal-title":"N Engl J Med"},{"key":"5709_CR18","unstructured":"WHO. Toxicity grading scale for determining the severity of clinical adverse events. Geneva: World Health Organization; 2003."},{"key":"5709_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009781","volume":"15","author":"T Ketema","year":"2021","unstructured":"Ketema T, Bacha K, Getahun K, Portillo HAdel, Bassat Q. Plasmodium vivax epidemiology in Ethiopia 2000-2020: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021;15:e0009781.","journal-title":"PLoS Negl Trop Dis"},{"key":"5709_CR20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/infdis\/jiz126","volume":"220","author":"KR Rijal","year":"2019","unstructured":"Rijal KR, Adhikari B, Ghimire P, Banjara MR, Das Thakur G, Hanboonkunupakarn B, et al. Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal. J Infect Dis. 2019;220:448\u201356.","journal-title":"J Infect Dis"},{"key":"5709_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12936-019-2981-x","volume":"18","author":"E Lo","year":"2019","unstructured":"Lo E, Zhong D, Raya B, Pestana K, Koepfli C, Lee M-C, et al. Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. Malar J. 2019;18:340.","journal-title":"Malar J"},{"key":"5709_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12916-019-1386-6","volume":"17","author":"RJ Commons","year":"2019","unstructured":"Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, et al. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Med. 2019;17:151.","journal-title":"BMC Med"},{"key":"5709_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1473-3099(23)00431-0","volume":"24","author":"M Rajasekhar","year":"2024","unstructured":"Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:184\u201395.","journal-title":"Lancet Infect Dis"},{"key":"5709_CR24","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14787210.2016.1220304","volume":"14","author":"CS Chu","year":"2016","unstructured":"Chu CS, White NJ. Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther. 2016;14:885\u2013900.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5709_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1475-2875-13-418","volume":"13","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.","journal-title":"Malar J"},{"key":"5709_CR26","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMoa2104226","volume":"386","author":"NN Chamma-Siqueira","year":"2022","unstructured":"Chamma-Siqueira NN, Negreiros SC, Ballard S-B, Farias S, Silva SP, Chenet SM, et al. Higher-dose primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2022;386:1244\u201353.","journal-title":"N Engl J Med"},{"key":"5709_CR27","unstructured":"Worldwide Antimalarial Resistance Network (WWARN). Management of acute hemolysis (primaquine for P vivax). v1.0. 2018."},{"key":"5709_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002379","volume":"14","author":"NM Douglas","year":"2017","unstructured":"Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med. 2017;14:e1002379.","journal-title":"PLoS Med"},{"key":"5709_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0035-9203(03)00041-5","volume":"98","author":"T Leslie","year":"2004","unstructured":"Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, et al. Compliance with 14-day primaquine therapy for radical cure of vivax malaria\u2014a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg. 2004;98:168\u201373.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5709_CR30","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1016\/S2214-109X(23)00542-9","volume":"12","author":"M Brito","year":"2024","unstructured":"Brito M, Rufatto R, Murta F, Sampaio V, Balieiro P, Ba\u00eda-Silva D, et al. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis. Lancet Glob Health. 2024;12:e467\u201377.","journal-title":"Lancet Glob Health"},{"key":"5709_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1473-3099(23)00430-9","volume":"24","author":"RJ Commons","year":"2024","unstructured":"Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:172\u201383.","journal-title":"Lancet Infect Dis"},{"key":"5709_CR32","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/S0140-6736(23)01553-2","volume":"402","author":"K Thriemer","year":"2023","unstructured":"Thriemer K, Degaga TS, Christian M, Alam MS, Rajasekhar M, Ley B, et al. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P. falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. Lancet. 2023;402:2101\u201310.","journal-title":"Lancet"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05709-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:06:43Z","timestamp":1768342003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-025-05709-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5709"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05709-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study obtained ethical approval from the Ethiopian Public Health Institute (EPHI), Tulane University School of Public Health and Tropical Medicine, and the US Centers for Disease Control and Prevention (#7151) institutional review boards. Before initiation of the study, all study participants were informed about the purpose and their right to refuse or withdraw at any time without compromising the standard care they would receive from the health facility. They were also informed about the intended use of the results for scientific publications and reports. Written consent and assent (where applicable) were obtained from each participant and parent\/guardian for minors (age\u2009<\u200918\u00a0years).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the United States Agency for International Development, or the U.S. President\u2019s Malaria Initiative.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}